We previously reported rapid resolution of hyperbilirubinemia using high-dose methylprednisolone (MP) in 61% of 28 hematopoietic stem cell transplant recipients who developed post transplant hepatic regimen-related toxicities (RRT). 1 This approach was subsequently adopted and applied to all patients with hepatic RRT at our institution. Between July 1998 and July 2002, 25 adult recipients of autologous, allogeneic related, or unrelated donor stem cell transplant (representing 2.4% of 1027 consecutive transplants) developed unexplained hyperbilirubinemia (serum bilirubin X4 mg/dl) clinically compatible with hepatic RRT and received MP intravenously at a dose of 500 mg/m 2 twice daily for a total of six doses. There was no overlap with patient data previously reported. Demographic characteristics, transplant information, and risk factors for veno-occlusive disease (VOD) for 24 patients in whom complete data were available are summarized in the table below. Treatment with high-dose MP was initiated a median 6 days (2-17 days) post transplant, and 1 day (0-4 days) from onset of hyperbilirubinemia. At 10 days after initiation of MP, response, defined as a 50% reduction in serum bilirubin, was observed in only eight patients (33%). The median total serum bilirubin in the responding patients decreased from 4.5 mg/dl (4-6.9) to 1.7 mg/dl (0.8-2.5), while a steady rise in serum bilirubin was observed in the nonresponding patients from a median 5 mg/dl (4-9.1) at the start of MP to 10.6 mg/dl (2.7-28.4) 10 days later. Neither prior administration of gemtuzumab nor administration of azole antifungal agents prior to the development of hyperbilirubinemia differed significantly between the two groups. Mortality among responding patients was mainly due to GVHD or relapse (21%), while organ failure and infection accounted for 58% of deaths in the nonresponding group. This follow-up analysis demonstrated a lower response rate of hepatic RRT to HDMP compared to our previous report. The discordant results question the role high-dose MP plays in the management of hepatic RRT. Clinical management of hepatic RRT at Washington University may have been influenced by the results of the previous analysis. Practitioners may have been more likely to begin treatment with high-dose methylprednisolone earlier in hopes of altering the course of hepatic RRT from July 1998 to July 2002. Unfortunately, conducting a randomized, controlled trial to answer this question is unrealistic taking into account the low incidence of VOD/hepatic RRT (2.4%) and the inaccuracy of current noninvasive methods to establish the diagnosis. Therefore, in light of this follow-up analysis, high-dose MP should only be administered to patients with non-GVHD hepatic RRT in the setting of a clinical trial. 
